What to expect: Enrolling on a cancer clinical trial during the COVID-19 pandemic

The COVID-19 pandemic has resulted in a number of changes to patient care, particularly in hospitals with high numbers of COVID-19 cases. For some patients with cancer, the pandemic has resulted in changes to their treatment and/or the replacement of in-person hospital visits with virtual patient assessments. The COVID-19 pandemic has also led to adaptations […]

read more

How the coronavirus pandemic may affect cancer clinical trials

In this article published in Cancer Therapy Advisor this week, changes to how clinical trials are being conducted due to the health risks posed by COVID-19 to cancer patients are discussed. Some of these changes include the use of telemedicine visits, electronic signatures for signing patient consent forms, posting oral medicines to patients’ homes, and […]

read more

Clinical research cut by 87% at peak of COVID-19 pandemic

Research from University College London published in PLOS One estimated that at the peak of the COVID-19 pandemic, clinical research capacity may have been slashed by up to 87% in England. The researchers estimated that at a population infection rate of 10% (the peak in April for over a month) less than 400 of the […]

read more

ASCO GU 2020: Randomised clinical trial of HIF-2α inhibitor in patients with advanced kidney cancer

A randomised clinical trial of hypoxia inducible factor 2α (HIF-2α) inhibitor, MK-6482, was announced at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco last weekend. HIF-2α is known to stimulate the growth of tumours via the von Hippel-Lindau (VLH) group of genes. MK-6482 (also known as PT2977) blocks the […]

read more

Real world use of targeted therapies in war veterans with kidney cancer

A retrospective study of the use of targeted therapies for advanced renal cell carcinoma (RCC) in war veterans in the USA reported poorer overall survival outcomes than those from clinical trials, as well as shorter treatment durations for first-line therapies with more frequent adverse events, dose reductions, and drug discontinuations. The study was published in […]

read more

ESMO 2019: IKCC global patient survey of kidney cancer patients in 43 countries

Results from the International Kidney Cancer Coalition (IKCC) global patient survey, conducted in 43 countries and almost 2,000 kidney cancer patients and carers, were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona earlier this month. In this video interview, Dr Eric Jonasch, medical oncologist from the University of Texas MD Anderson […]

read more

Kidney cancer clinical trials: What you need to know

In this article, Deb Maskens, founder of Kidney Cancer Canada and board director of the International Kidney Cancer Coalition (IKCC) recommends that patients with kidney cancer should be thinking about clinical trials at every step of their journey, not just after a line of therapy has stopped working for them. Ms Maskens, an advanced kidney […]

read more

Promising early studies with pegilodecakin plus immunotherapy in pretreated kidney cancer

A recent phase 1b clinical trial investigated the use of pegilodecakin in combination with anti-PD-1 monoclonal antibodies nivolumab or pembrolizumab. The combination showed a “favourable” response in patients with non-small cell lung cancer and kidney cancer. Pegilodecakin works by stimulating the survival, proliferation and “killing” potential of CD8+ T cells, which can recognise and destroy […]

read more

Phase Ib cabozantinib plus atezolizumab combination study now open to kidney cancer patients in the UK

Based on promising efficacy findings, the COSMIC-021 clinical trial has been expanded from the original two indications (non-small cell lung cancer (NSCLC) and prostate cancer) and is now open to patients with renal cell carcinoma (RCC), urothelial cancer, breast cancer and ovarian cancer. The phase 1b, open-label trial assesses the combination of cabozantinib (Cabometyx) and […]

read more

NICE exploring ways to use real world data

The National Institute of Health and Care Excellence (NICE) is planning to extend its use of real world data to help inform its independent committees who produce its guidance. NICE already makes use of a wide range of published scientific evidence for its guidance for the NHS on health technologies for a range of medical […]

read more
Showing 1 to 10 of 24 results
  TOP